Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Operating Expenses:
Research and development	$ 2,988	$ 2,123	$ 5,026	$ 4,385
General and administrative	2,358	2,146	4,912	5,043
Total operating expenses	5,346	4,269	9,938	9,428
Operating loss	(5,346)	(4,269)	(9,938)	(9,428)
Other income (expense):
Investment income, net	209	194	436	371
Interest expense	0	(2)	0	(5)
Total other income (expense), net	209	192	436	366
Net loss	(5,137)	(4,077)	(9,502)	(9,062)
Less - net income (loss) attributable to noncontrolling interests	3	(1)	5	(3)
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	$ (5,140)	$ (4,076)	$ (9,507)	$ (9,059)
Basic and diluted loss per share
Caladrius Biosciences, Inc. common stockholders (in usd per share)	$ (0.49)	$ (0.42)	$ (0.93)	$ (0.95)
Weighted average common shares outstanding
Basic and diluted shares	10,393	9,592	10,211	9,577